Rapid Rx Quiz: Myasthenia Gravis Treatments

Mary L. Windle, PharmD


March 15, 2022

Eculizumab is approved by the FDA in patients for generalized MG who test positive for AchR antibodies. Approval was based on data from the REGAIN phase 3 trial that compared eculizumab with placebo. The primary efficacy endpoint for generalized MG was a comparison of the change from baseline between treatment groups according to  Myasthenia Gravis-Activities of Daily Living (MG-ADL) total score at week 26. Treatment with eculizumab showed a statistically significant difference in the mean change from baseline to week 26 in MG-ADL total scores (-4.2 points vs -2.3 points). In the open-label extension phase, MG exacerbation rate was reduced by 75% compared with the previous year in patients taking eculizumab (P < .0001). Additional C5 inhibitors (eg, zilucoplan; RAISE phase 3 trial [NCT04115293]) are completing phase 3 trials that show similar encouraging results.

Learn more about other treatments for MG.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.